Anti-angiogenic therapy is an anti-cancer
strategy that targets the new vessels that grow to provide oxygen and nutrients
to actively proliferating tumor cells. Most of the current anti-cancer reagents
used in the clinical setting indiscriminately target all rapidly dividing
cells, resulting in severe adverse effects such as immunosuppression,
intestinal problems and hair loss. In comparison, anti-angiogenic reagents
theoretically have fewer side effects because, except in the uterine
endometrium, neoangiogenesis rarely occurs in healthy adults. Currently, the
most established approach for limiting tumor angiogenesis is blockade of the
vascular endothelial growth factor (VEGF) pathway. In line with the results of
preclinical studies, significant therapeutic effects of VEGF blockers have been
reported in various types of human cancers, even in patients with
progressive/recurrent cancer who could not otherwise be treated. However, some
patients are refractory to this treatment or acquire resistance to VEGF
inhibitors. Moreover, several studies have shown that VEGF blockade damages
healthy vessels and results in adverse effects such as hemorrhagic and
thrombotic events. In recent research that indicated possible ways to overcome
these problems, several VEGF-independent and tumor-selective pro-angiogenic
mechanisms were discovered that could be targeted in combination with or
without conventional VEGF blockade. These findings offer opportunities to
greatly improve current anti-angiogenic treatment for cancer.
Source: Tumor Angiogenesis and
Anti-angiogenic Therapy. Kubota Y
(ykubo33@a3.keio.jp). Keio J Med. 2012 May;61(2):47-56.
Free paper available at:
I would like to know more about that therapy. I am so anxious to see what are the great changes and help that it can bring to someone who has cancer. My alternative cancer treatment center would like to know more about the same.
RépondreSupprimer